Patent US4011142A successfully refreshed from Google Patents.
US4011142A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for measuring the plasminogen content of a sample
Assignee: Siemens Healthcare Diagnostics GmbH Germany
•
Filing: 1975-01-15
•
Granted: 1977-03-08
•
Expires: 1995-01-15
Abstract
Abstract The plasminogen content of a blood sample is measured by determining the rate of formation of fibrin in a sample in which antiplasmin-free plasminogen is activated to form plasmin before the onset of fibrin formation so that the plasmin-conditioned break-down of the fibrin occurs simultaneously with formation of fibrin.
Inventors
- 👤 Eckart Jacobi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 23:13
CPC Classifications
C; C12; C12Q; C12Q1/00; C12Q1/34; C12Q1/37; C12Q1/56; G; G01; G01N; G01N2333/00; G01N2333/435; G01N2333/745; G01N2333/75; G01N2333/90; G01N2333/914; G01N2333/948; G01N2333/968
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
111 words
The process of measuring the plasminogen content of a plasma sample comprising the steps of: a. eliminating any antiplasmin from the plasma sample, b. adding a predetermined amount of fibrinogen to the sample, c. adding an amount of plasminogen activator sufficient to activate all possible plasminogen present in the sample, and d. incubating the sample a sufficient period of time to form a solution of fibrinogen and antiplasmin-free, plasminogen-activated plasma, e. adding thrombin to the solution, and f. timing the reaction until the moment of fibrin coagulation is observed in the solution, the plasminogen content to be established by comparing the observed time to fibrin coagulation with an established normal standard.
Claim 2
Dependent Claim
111 words
The process of measuring the plasminogen content of a plasma sample comprising the steps of: a. eliminating any antiplasmin from the plasma sample, b. adding a predetermined amount of fibrinogen to the sample, c. adding an amount of plasminogen activator sufficient to activate all possible plasminogen present in the sample, and d. incubating the sample a sufficient period of time to form a solution of fibrinogen and antiplasmin-free, plasminogen-activated plasma, e. adding thrombin to the solution, and f. timing the reaction until the moment of fibrin coagulation is observed in the solution, the plasminogen content to be established by comparing the observed time to fibrin coagulation with an established normal standard.
Claim 3
Dependent Claim
125 words
The process of measuring the plasminogen content of a plasma sample comprising the steps of: a. eliminating any antiplasmin from the plasma sample, b. adding a predetermined amount of fibrinogen to the sample, c. selecting a plasminogen activator from the group consisting of urokinase and streptokinase, d. adding an amount of the selected plasminogen activator sufficient to activate all possible plasminogen present in the sample, e. incubating the sample a sufficient period of time to form a solution of fibrinogen and antiplasmin-free, plasminogen-activated plasma, f. adding thrombin to the solution, and g. timing the reaction until the moment of fibrin coagulation is observed in the solution, the plasminogen content to be established by comparing the observed time to fibrin coagulation with an established normal standard.
Claim 4
Dependent Claim
125 words
The process of measuring the plasminogen content of a plasma sample comprising the steps of: a. eliminating any antiplasmin from the plasma sample, b. adding a predetermined amount of fibrinogen to the sample, c. selecting a plasminogen activator from the group consisting of urokinase and streptokinase, d. adding an amount of the selected plasminogen activator sufficient to activate all possible plasminogen present in the sample, e. incubating the sample a sufficient period of time to form a solution of fibrinogen and antiplasmin-free, plasminogen-activated plasma, f. adding thrombin to the solution, and g. timing the reaction until the moment of fibrin coagulation is observed in the solution, the plasminogen content to be established by comparing the observed time to fibrin coagulation with an established normal standard.
Claim 5
Dependent Claim
23 words
The process of claim 2 wherein the antiplasmins are removed from the plasma sample in step (a.) by washing the sample with isoamylalcohol.
Claim 6
Dependent Claim
15 words
The process of claim 2 wherein the plasminogen activator used in step (c.) is urokinase.
Claim 7
Dependent Claim
15 words
The process of claim 2 wherein the plasminogen activator used in step (c.) is streptokinase.
Claim 8
Dependent Claim
24 words
The process of claim 5 wherein the streptokinase is added to the fibrinogen of step (b.) before the fibrinogen is added to the sample.
Claim 9
Dependent Claim
27 words
The process of claim 6 wherein an additional amount of plasminogen is added to the fibrinogen of step (b.) before the fibrinogen is added to the sample.
Claim 10
Dependent Claim
33 words
The process of claim 6 wherein the streptokinase and fibrinogen are stored before use in the dry state and are brought into solution together in one operation by the addition of a solvent.
References Cited (Backward Citations)
US3853710A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-03-07 | 1980-09-06 | 1981-03-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-03-07 | 1984-09-06 | 1985-03-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-03-07 | 1988-09-06 | 1989-03-08 | $7700.00 | Window Closed / Lapsed |